Francis Pebalo Pebolo
ID: UNCST-2022-R010630
|
Incidence, risk factors and clinical outcomes of neonatal sepsis among HIV-exposed infants of mothers on dolutegravir-based antiretroviral therapy in Uganda
REFNo: HS6486ES
Comparing 28-day clinical outcomes of mothers with HIV on DTG-based ART compared with their HIV negative counterparts.,To compare 28-day clinical outcomes among HIV-exposed neonates of mothers on DTG-based ART and HIV-unexposed neonates.,To compare sepsis incidence risk factors among HIV-exposed neonates of mothers on DTG-based ART and HIV-unexposed neonates,To conduct a scoping review to describe the epidemiology of neonatal sepsis of neonates born to mothers with HIV comparing outcomes on DTG- and non-DTG-containing regimens,
|
Uganda |
2025-11-04 13:00:07 |
2028-11-04 |
Medical and Health Sciences |
|
Degree Award |
|
ERIC WOBUDEYA
ID: UNCST-2019-R001047
|
Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV
REFNo: HS6555ES
Primary Objectives
Cohort 1 and Cohort 2
• To determine the weight-band dosing of RPT taken as part of the 1HP regimen by evaluating:
? PK RPT exposures among children with and without HIV
? Safety and tolerability of the 1HP regimen among children with HIV while receiving twice-daily DTG and children without HIV through 28 days of dosing
Cohort 2
• To evaluate the effect of RPT taken as part of the 1HP regimen on the PK of DTG
Secondary Objectives
Cohort 1 and Cohort 2
• To evaluate the effect of covariates including age, weight, sex, ethnicity, nutritional status, and HIV-1 status on the PK of RPT taken as part of the 1HP regimen
• To evaluate the safety of the 1HP regimen through 24 weeks of follow-up
• To evaluate the palatability and acceptability of the 1HP regimen
• To evaluate adherence to the 1HP regimen
Cohort 2
• To evaluate the safety and tolerability of twice-daily DTG through 42 days among children with HIV who are receiving 1HP
• To evaluate virologic control (less than 200 copies/mL) at Day 42 among children taking a DTG-based ARV treatment regimen co-administered with 1HP
|
Uganda |
2025-11-04 12:59:17 |
2028-11-04 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Isaac Ssewanyana
ID: UNCST-2020-R014336
|
ConfiSign HIV/Syphilis Combo Self-Test: Evaluation of Clinical Performance and Usability in the hands of untrained users.
REFNo: HS6687ES
Untrained users will either take part in the label comprehension study and results interpretation study (part A) or in the observed untrained user study (part B). Untrained users enrolled for the label comprehension and results interpretation study (part A), shall not participate in the observed user study (part B) and vice versa.,The primary and overall objective of this study is to evaluate the performance and the usability of the ConfiSign HIV/Syphilis Combo Self-Test in the hands of untrained users from a low prevalence HIV region (< 5%) who have no, or limited experience in self-testing. ,
|
Uganda |
2025-10-29 16:22:26 |
2028-10-29 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Specioza Namakula
ID: UNCST-2025-R021710
|
EMPOWERING MOBILITY: Assessing the Impact of Buffalo Bicycles on Refugee and host Communities in Uganda. A case study of Bidi Bidi, Rhino Camp and Palabek refugee settlements
REFNo: SS4566ES
I. To generate data that will support Learning and evidence-based decision making.
II. To provide systematic and objective information for bicycle usage in refugee communities.
III. Generating information that is required to inform advocacy and further bicycle provision for vulnerable communities.
IV. To determine the effectiveness, efficiency and relevance of bicycles in improving accessibility to essential services like education, health and economic empowerment.
|
Uganda |
2025-10-29 16:20:00 |
2028-10-29 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Victor Musiime -
ID: UNCST-2021-R013794
|
Enhancing Novel Research for Inflammation and Cognitive Health among Adolescents and Young Adults Living with Perinatally Acquired HIV and Adversity (ENRICH+)
REFNo: HS6607ES
Specific Aim 1: Investigate differences in ID and NCI in demographically matched, virally suppressed PHIV and HHIV, as well as HUU AYA (15-25 years old) in Uganda while controlling for chronic adversities. Hypothesis 1 (H1): Both ID and NCI will be respectively higher in PHIV vs. HHIV vs. HUU AYA. H2: Within the two HIV groups, those with delayed ART initiation and lower nadir CD4 cell count at ART initiation will have higher ID and worse NCI.
Specific Aim 2: Investigate the relationship between ID and NCI in AYA within all three groups (PHIV, HHIV and HUU) controlling for chronic adversities. H3: There will be a positive association between ID and NCI in each group. H4: In a subset of PHIV and HUU AYA with prior repeated measures of ID, worsening trajectories of ID in PHIV across 6 years will be associated with worse NCI.
Specific Aim 3: Investigate the effects of co-occurring adversities (i.e., profiles) on the relationships between HIV, ID, and NCI. H5: Adversity profiles will be more severe respectively in PHIV vs. HHIV vs. HUU. H6: The strength of association between medical and psychosocial (e.g., stigma, mental health) adversities, ID and NCI will be strongest in PHIV vs. HHIV vs. HUU, respectively.
|
Uganda |
2025-10-29 16:07:10 |
2028-10-29 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|